 |
Find a Stock's Home Page |
|
| Small Cap Stock Analysis |
Gaining 20.58% ($0.50) in early trading this morning is Helicos BioSciences Inc., (HLCS) http://www.helicosbio.com/ currently trading on the Nasdaq in the $2.93 range. HLCS has a new market cap of $190 million. HLCS has a 3-Month average daily trading volume of 2,062,740 and it rippled that volume, surpassing 6,483,342 an hour into today's trading session.
HLCS management announced this morning the life science company's True Single Molecule Sequencing technology was successfully used to directly sequence individual molecules of RNA. The study was initially revealed in a paper posted in the on-line edition of Nature yesterday.
The HLCS study consists of the accurate sequencing and quantitation of RNA molecules obtained directly from a biological sample without amplification, ligation or cDNA synthesis.
"Direct RNA sequencing is the first example of the innovative methods that can only be performed using true single molecule sequencing," noted Patrice Milos, PhD, VP and HLCS Chief Scientific Officer in a press release this morning.
"Scientists, for the first time, will be able to analyze the RNA from their samples directly, completely eliminating the biases inherent to traditional RNA analysis techniques that rely on copying cDNA from RNA," he added.
"This exciting work demonstrates that our technology enables a new set of methods and applications that were previously impossible, and that Helicos' single-molecule sequencing system is truly unique in the genetic analysis market," said Ron Lowy, CEO of HLCS.
HLCS has a proprietary system called Genetic Analysis and it is world's first and only commercially available, single molecule sequencing technology that enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. HLCS was founded in 2003 and is headquartered in Cambridge, Massachusetts.
At $2.93, HLCS is below its 52-week high of $3.54 set on 08-31-09 and is above its 52-week low of $0.21 set on 12-17-08. At $2.93, HLCS is ahead of both its 50-day and 200-day moving averages. HLCS is widely held by insiders. It shares out versus float ratio is 64m/29m but it is liquid and stable at its average trading volume though I would like to see more shares in the public float.
Sign-up for Free to Receive Future Commentary and Trading Alerts on HLCS
